Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) has been halted ahead of today FDA AdCom to review the New Drug Application (NDA) for eteplirsen.
After plunging last Thursday on negative-biased FDA briefing documents, shares surged on Friday on positive draft questions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA accepts Sarepta's applications to convert two DMD drugs to full approval
- Midera Food Processing and Centrus Energy to join S&P SmallCap 600
- Trump: Musk relationship 'very good' - CNBC Interview
Create E-mail Alert Related Categories
FDA, Trader Talk, Trading HaltsRelated Entities
AdComSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
